Assessment of health‐related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's)
Open Access
- 27 September 2011
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 64 (2), 273-279
- https://doi.org/10.1002/acr.20649
Abstract
Objective To assess a generic measure of health‐related quality of life (HRQOL) as an outcome measure in granulomatosis with polyangiitis (Wegener's) (GPA). Methods Subjects were participants in the Wegener's Granulomatosis Etanercept Trial (WGET) or the Vasculitis Clinical Research Consortium Longitudinal Study (VCRC‐LS). HRQOL was assessed with the Short Form 36 (SF‐36) health survey that includes physical and mental component summary scores (PCS and MCS, respectively). Disease activity was assessed with the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG). Results The data from 180 subjects in the WGET (median followup 2.3 years, mean number of visits 10) and 237 subjects in the VCRC‐LS (median followup 2.0 years, mean number of visits 8) were analyzed. A 1 unit increase in the BVAS/WG corresponded to a 1.15 unit (95% confidence interval [95% CI] 1.02, 1.29) decrease for the PCS and a 0.93 (95% CI 0.78, 1.07) decrease for the MCS in the WGET, and to a 1.16 unit decrease for the PCS (95% CI 0.94, 1.39) and a 0.79 unit decrease for the MCS (95% CI 0.51, 1.39) in the VCRC‐LS. In both arms of the WGET study, SF‐36 measures improved rapidly during the first 6 weeks of treatment followed by gradual improvement among patients achieving sustained remission (0.5 improvement in PCS per 3 months), but worsened slightly (0.03 decrease in PCS every 3 months) among patients not achieving sustained remission (P = 0.005). Conclusion HRQOL, as measured by the SF‐36, is reduced among patients with GPA. SF‐36 measures are modestly associated with other disease outcomes and discriminate between disease states of importance in GPA.Keywords
This publication has 31 references indexed in Scilit:
- The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated VasculitisThe Journal of Rheumatology, 2011
- Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitisArthritis Care & Research, 2011
- Patient‐reported outcome assessment in vasculitis may provide important data and a unique perspectiveArthritis Care & Research, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9The Journal of Rheumatology, 2009
- Assessment of damage in vasculitis: expert ratings of damageRheumatology, 2009
- Health‐related quality of life for patients with vasculitis and their spousesArthritis Care & Research, 2009
- EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitisAnnals Of The Rheumatic Diseases, 2007
- The MOS 36-Item Short-Form Health Survey (SF-36)Medical Care, 1993
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992